Aptose Biosciences (NASDAQ:APTO) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.
Profitability
This table compares Aptose Biosciences and Dyadic International's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Aptose Biosciences | N/A | -49.53% | -46.65% |
| Dyadic International | -539.34% | -27.54% | -26.33% |
Earnings and Valuation
This table compares Aptose Biosciences and Dyadic International's gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Aptose Biosciences | N/A | N/A | $-26,280,000.00 | ($0.52) | -9.35 |
| Dyadic International | $1.68 million | 62.65 | $-8,310,000.00 | ($0.31) | -12.32 |
Dyadic International has higher revenue and earnings than Aptose Biosciences. Dyadic International is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations and price targets for Aptose Biosciences and Dyadic International, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Aptose Biosciences | 0 | 0 | 8 | 0 | 3.00 |
| Dyadic International | 0 | 0 | 1 | 0 | 3.00 |
Aptose Biosciences currently has a consensus price target of $11.6250, indicating a potential upside of 139.69%. Dyadic International has a consensus price target of $11.00, indicating a potential upside of 183.51%. Given Dyadic International's higher possible upside, analysts plainly believe Dyadic International is more favorable than Aptose Biosciences.
Volatility and Risk
Aptose Biosciences has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500.
Insider & Institutional Ownership
52.2% of Aptose Biosciences shares are owned by institutional investors. Comparatively, 20.2% of Dyadic International shares are owned by institutional investors. 6.3% of Aptose Biosciences shares are owned by insiders. Comparatively, 23.9% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Dyadic International beats Aptose Biosciences on 7 of the 12 factors compared between the two stocks.
